Table 2.
Summary of Multivariate Regressions Modeling Neuropsychological Performance
| Model A. NP performance as a function of antiretroviral resistance, meth abuse, HIV infection duration, and ARV use | ||
|---|---|---|
| Coefficient | p-value | |
| Intercept | 3.96 | <0.0001 |
| Antiretroviral Resistance (blood) | −0.88 | 0.02 |
| Duration of HIV (years) | 0.07 | 0.06 |
| Methamphetamine Abuse Ever | 0.76 | 0.03 |
| ARV Use | 0.38 | 0.40 |
| Adjusted R2=0.12 | ||
| Model B. NP performance as a function of antiretroviral resistance, meth abuse, HIV infection duration, and ARV use and CSF HIV RNA levels | ||
|---|---|---|
| Coefficient | p-value | |
| Intercept | 3.31 | <0.0001 |
| Antiretroviral Resistance (blood) | −0.79 | 0.05 |
| Duration of HIV (years) | 0.07 | 0.06 |
| Methamphetamine Abuse Ever | 0.83 | 0.02 |
| ARV Use | 0.47 | 0.31 |
| HIV RNA, CSF (log10 c/mL) | 0.18 | 0.35 |
| Adjusted R2=0.12 | ||
| Model C. NP performance as a function of antiretroviral resistance, meth abuse, HIV infection duration, and ARV use and plasma HIV RNA levels | ||
|---|---|---|
| Coefficient | p-value | |
| Intercept | 3.33 | <0.0001 |
| Antiretroviral Resistance (blood) | −0.67 | 0.04 |
| Duration of HIV (years) | 0.04 | 0.23 |
| Methamphetamine Abuse Ever | 0.76 | 0.01 |
| ARV Use | 0.56 | 0.16 |
| HIV RNA, Plasma (log10 c/mL) | 0.150 | 0.45 |
| Adjusted R2=.09 | ||
In multivariate analysis, antiretroviral resistance was found to be associated with NP performance, although no significant relationship between CSF HIV RNA and NP performance was observed. Antiretroviral use, blood viral load and CSF viral load did not explain additional variance in NP performance.